What You Should Know:
– AI-driven virtual care company, GYANT, has announced its first-to-market COVID-19 vaccine care navigation tool to help health systems anticipate novel patient needs.
– GYANT Vaccine deploys as a white-labeled virtual assistant on provider websites, mobile apps, and patient portals, managing the patient journey from initial inquiry to post-visit follow up.
GYANT, the AI-powered virtual assistant company, today announced its first-to-market vaccine care navigation tool, GYANT Vaccine, anticipating impending health system strain following emergency use authorization of a COVID-19 vaccine. The solution offers support for each step of the patient journey, from initial inquiry to post-vaccination follow-up.
GYANT Vaccine builds on the company’s successful COVID-19 SERA technology, which rapidly helped 25 payer and health system customers and half a million patients screen and triage symptoms to access testing and care. With the addition of Vaccine, GYANT’s AI-powered virtual assistant platform now even more effectively connects the dots across patients’ digital journeys with the existing Front Door (care navigation and triage), Engage (patient outreach) and Clipboard (automated chart population) modules.
Is Your Health System Prepared for the Vaccine?
Anticipating the tsunami of inbound patient inquiries, overwhelmed call centers, appointment scheduling demands, and eligibility screening requests as the vaccine becomes available, GYANT Vaccine will virtually guide patients through the entire pre- and post-vaccination process
GYANT Vaccine deploys as a white-labeled virtual assistant on provider websites, mobile apps, and patient portals, managing the patient journey from initial inquiry to post-visit follow up. GYANT Vaccine is available 24/7, to relieve the burden of administrative staff, simplify the research and appointment scheduling for consumers, and keep patients safe.
By empowering patients to learn about processes and options, screen and assess prioritization, book appointments, and stay in touch with their providers to schedule additional doses and monitor for side effects, GYANT Vaccine adapts to each provider’s changing requirements over the course of the vaccine roll-out.
“Navigating the deployment of the COVID-19 vaccine will be the single biggest challenge healthcare systems face in 2021,” said Stefan Behrens, co-founder and chief executive officer, GYANT. “With our help, customers are poised to effectively anticipate and manage the vaccine’s deployment whenever it is approved, and play a role in controlled widespread adoption as we seek to overcome this crisis.”
GYANT Vaccine has already generated overwhelming interest in the market with five health systems signed on to deploy the tool following emergency use authorization of a vaccine.